The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 18, 2016

Filed:

Aug. 10, 2015
Applicant:

Abbvie Inc., North Chicago, IL (US);

Inventors:

Lorenzo Benatuil, Northborough, MA (US);

Erwin R. Boghaert, Pleasant Prairie, WI (US);

Jijie Gu, Shrewsbury, MA (US);

Maria Harris, Shrewsbury, MA (US);

Jonathan A. Hickson, Lake Villa, IL (US);

Chung-Ming Hsieh, Newton, MA (US);

Yuliya Kutskova, Northborough, MA (US);

Yingchun Li, Buffalo Grove, IL (US);

Zhihong Liu, Gurnee, IL (US);

Susan Morgan-Lappe, Riverwoods, IL (US);

Assignee:

AbbVie Inc., North Chicago, IL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07H 21/04 (2006.01); C07K 16/22 (2006.01); C07K 14/47 (2006.01); C07K 16/18 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 7/06 (2006.01); C07K 7/08 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 7/06 (2013.01); C07K 7/08 (2013.01); C07K 14/47 (2013.01); C07K 16/18 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.


Find Patent Forward Citations

Loading…